Ican

Ican

irinotecan

Manufacturer:

Bliss Pharma

Distributor:

Multicare

Marketer:

Multicare
Concise Prescribing Info
Contents
Irinotecan HCl
Indications/Uses
Metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
Dosage/Direction for Use
Combination therapy for the treatment of colorectal cancer Irinotecan 125 mg/m2 as IV 90 min on days 1, 8, 15 & 22 followed by leucovorin 20 mg/m2 as IV bolus on same days. 5-FU 500 mg immediately administer after administration of leucovorin, thereafter, additional courses are repeated after every 6 wk (4 wk on therapy, 2 wk off therapy).
Contraindications
Special Precautions
Avoid extravasation. Patients who previously received pelvic/abdominal irradiation. Hepatic dysfunction. Myelosuppression. Careful monitoring of WBC w/ differential, Hb & platelet count is recommended. Pregnancy & lactation. Elderly >65 yr.
Adverse Reactions
Nausea, vomiting & diarrhea; neutropenia, leukopenia (including lymphocytopenia) & anemia; asthenia, fever & abdominal pain; rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing & intestinal hyperperistalsis; hepatic metastasis; alopecia; vasodilation.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CE02 - irinotecan ; Belongs to the class of Topoisomerase 1 (TOP1) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Ican soln for inj 20 mg/mL
Packing/Price
(100 mg/5 mL) 1's; (40 mg/2 mL) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in